This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Insulet (PODD) Q4 Earnings, Revenues Top Mark, Margins Expand
by Zacks Equity Research
In the fourth quarter, Insulet (PODD) achieves the milestone of 425,000 estimated active global customers using Omnipod products.
Alcon (ALC) Faces Rising Expenses, Tough Competitive Scenario
by Zacks Equity Research
In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.
Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances
by Zacks Equity Research
Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Down -15.31% in 4 Weeks, Here's Why You Should You Buy the Dip in Insulet (PODD)
by Zacks Equity Research
Insulet (PODD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Bruker's (BRKR) New Launches Drive Growth Amid FX Woes
by Zacks Equity Research
Bruker's (BRKR) revenues continue to be driven by the strength of end markets, including academic and government, and industrial.
Charles River (CRL) Forges Collaboration With Wheeler Bio
by Zacks Equity Research
Charles River (CRL) and Wheeler Bio join forces to accelerate the journey from discovery and CMC development to manufacturing.
Insulet (PODD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Insulet (PODD) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 108.96% and 10.79%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Insulet (PODD) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Here's Why You Should Retain Insulet (PODD) Stock for Now
by Zacks Equity Research
The huge success of Omnipod 5 boosts investors' confidence in Insulet (PODD).
Insulet (PODD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Insulet (PODD) is expected to have benefited from the ongoing rollout of Omnipod 5 in several international markets in the fourth quarter.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
IDEXX's (IDXX) Global Growth Continues, Currency Woes Persist
by Zacks Equity Research
A key element of IDEXX's (IDXX) customer engagement strategy is the expansion of its commercial footprint in a disciplined approach.
Insulet's (PODD) Omnipod 5 Gets CE Mark for Added Compatibility
by Zacks Equity Research
Insulet's (PODD) tubeless automated insulin delivery system's CE mark approval with multiple CGM sensor brands is likely to serve a wider patient pool.
Edwards Lifesciences (EW) Wins FDA Nod for the EVOQUE System
by Zacks Equity Research
Edwards Lifesciences' (EW) EVOQUE valve replacement system becomes the first transcatheter therapy to earn FDA approval for a tricuspid valve.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Strength of the base business bodes well for Quest Diagnostics (DGX).
Insulet (PODD) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Insulet (PODD) could produce exceptional returns because of its solid growth attributes.
Boston Scientific's (BSX) FARAPULSE PFA System Gets FDA Nod
by Zacks Equity Research
Boston Scientific (BSX) secures FDA approval for the FARAPULSE PFA system.
Insulet (PODD) Gains From Product Innovation, Global Expansion
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.
Thermo Fisher (TMO) End Market Growth Strong Despite Macro Woes
by Zacks Equity Research
Thermo Fisher's (TMO) electron microscopy, chromatography and mass spectrometry businesses are delivering strong growth in the academic and government end market.
QIAGEN (QGEN) Forges Alliance to Advance Microbiome Sciences
by Zacks Equity Research
QIAGEN (QGEN) announces a first-in-kind collaboration with Penn State University to help shape research, education and outreach in microbiomes.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business.
Universal Health (UHS) Up 5.3% in 6 Months: More Room to Run?
by Zacks Equity Research
Universal Health's (UHS) rising patient volumes and better pricing position the company well for growth.
Here's Why Insulet (PODD) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.